Viking Therapeutics VKTX Other accrued liabilities
Other accrued liabilities at other companies
Other financials
Where this comes from
Reported directly by Viking Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OtherAccruedLiabilitiesCurrent.
The official record: Viking Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Viking Therapeutics's other accrued liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Viking Therapeutics's other accrued liabilities?
- Viking Therapeutics (VKTX) reported other accrued liabilities of $39.14M in Q1 2026.
- How has Viking Therapeutics's other accrued liabilities changed year-over-year?
- Viking Therapeutics's other accrued liabilities increased by 244.2% year-over-year, from $11.37M to $39.14M.
- What is the long-term trend for Viking Therapeutics's other accrued liabilities?
- Over 5 years (2020 to 2025), Viking Therapeutics's other accrued liabilities has grown at a 24.4% compound annual growth rate (CAGR), from $7.81M to $23.28M.